ASX healthcare stocks were not the bell of the ball in 2025.
In fact, the S&P/ASX 200 Health Care Index (ASX: XHJ) fell almost 25% in that span.
Two exceptions to this broader fall were Artrya Ltd (ASX: AYA) and 4DMedical Ltd (ASX: 4DX).
These two ASX healthcare stocks have rocketed between 300% and 500% in the last year.
However, both have dipped substantially in the last couple of weeks.
They may now be priced at an attractive entry point relative to 52-week highs.
Artrya
Artrya is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease.
Artrya's Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.
A year ago, its share price was hovering around $0.83 per share.
It hit an all-time high last week of more than $5 per share.
However, the share price has retreated over the last week and now sits significantly below the all-time high at approximately $3.38.
For prospective investors, all eyes will be on the company's expansion into the US market.
On January 30, the ASX healthcare stock released its quarterly activities report.
In the report, John Konstantopoulos, Co-Founder and CEO of Artrya, commented:
This Quarter has been pivotal for Artrya as we continue to build momentum in the U.S. market.
We achieved our first fee-per-scan revenues from the FDA-cleared Salix® Coronary Plaque module with Tanner Health, marking the commencement of recurring U.S. revenues alongside subscription income.
With Northeast Georgia Health System and Cone Health also executing commercial agreements, all three of our U.S. foundation partners have now converted to commercial customers, establishing a strong platform for expansion in 2026.
Last month, Wilson Asset Management listed this ASX healthcare stock as a buying opportunity.
The recent dip in share price could present an opportunity for prospective investors.
4DMedical
4DMedical is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
Its share price is up almost 500% in the last year.
However, it has shed almost 40% in the last 3 weeks of trading.
This includes a drop of more than 6% yesterday, closing at $3.15.
Estimates from brokers indicate this could be an attractive entry point for investors.
A recent share price target from Bell Potter of $4.50 indicates a potential upside of 42.86%.
The broker said 4DX has never been better positioned to make major inroads into the US market.
